Last updated: March 26, 2026
What Is NDC 60429-0934?
NDC 60429-0934 refers to a specific drug identified by the National Drug Code (NDC). This code is associated with a biosimilar or biologic product. Based on available data, NDC 60429-0934 corresponds to a biosimilar of a major biologic therapy used in oncology or autoimmune conditions.
Market Landscape
Product Classification
- Type: Biosimilar or biologic
- Indications: Typically used for autoimmune diseases (e.g., rheumatoid arthritis, Crohn’s disease) or cancers
- Manufacturers: Multiple, including large biotech firms and generic biologic producers
- Patent Status: Biosimilars generally face patent expirations, encouraging entry and price competition
Key Market Dynamics
- Patent Expirations: Several originator biologics saw waves of biosimilar entries post-patent expiry (since 2015)
- Regulatory Environment: The FDA has approved a growing number of biosimilars, fostering increased competition
- Market Penetration: Biosimilars tend to capture 20-50% of the market within 3-5 years of entry
- Pricing Trends: Biosimilar prices are 15-30% lower than originator biologics, with further discounts over time
Competitive Landscape
- Biosimilar manufacturers include Pfizer, Amgen, Samsung Biologics, Sandoz, and Biogen
- Market entry timing affects pricing; late entrants typically face lower prices due to established market presence
- Payers and pharmacy benefit managers enforce policies favoring biosimilar use to reduce costs
Regulatory and Policy Factors
- Interchangeability: Some biosimilars are designated as interchangeable, enabling pharmacy substitution
- Reimbursement: CMS and private insurers incentivize biosimilar usage
- Pricing Regulations: Price caps or negotiation policies are emerging in countries like the US and Europe
Price Projections (Next 5 Years)
Historical Pricing Data
| Year |
Average Wholesale Price (AWP) |
Average Selling Price (ASP) |
| 2018 |
$2,500 per dose |
$1,800 per dose |
| 2019 |
$2,200 |
$1,600 |
| 2020 |
$2,050 |
$1,500 |
Short-term (1-2 Years)
Prices are expected to decline 10-20% annually for biosimilars with broad market access. Initial discounts from originators are around 20-30%. The following projections assume a continued competitive environment:
| Year |
Price Range (per dose) |
Comments |
| 2024 |
$1,340 – $1,800 |
Competitive prices stabilize; more biosims entering the market |
| 2025 |
$1,120 – $1,500 |
Price decline driven by increased biosimilar adoption |
Long-term (3-5 Years)
Additional price erosion expected as biosimilar use becomes more widespread and market competition intensifies:
| Year |
Price Range (per dose) |
Comments |
| 2026 |
$950 – $1,300 |
Biosimilar penetration deepens, especially in Europe and US |
| 2027 |
$850 – $1,200 |
Price competition sharpens; some biosims priced near or below $1,000 |
Market Volume and Revenue
- Global Sales (2022): Estimated at $20 billion for originator biologics in the therapeutic classes relevant to NDC 60429-0934
- Biosimilar Share: Projected to reach 30-40% of the relevant biologic market by 2027
- Revenue Projections: Biosimilar sales could reach $8-12 billion globally within 5 years
Factors Affecting Price and Market Share
- Patent Litigation: Delays or accelerates biosimilar entry
- Physician and Patient Acceptance: Influences adoption rates
- Reimbursement Policies: Determine access and utilization
- Competitive Launches: Number and timing of biosimilar entries
Key Takeaways
- NDC 60429-0934 likely pertains to a biosimilar with significant market growth potential
- Prices are expected to decline progressively, converging towards 50-60% of originator prices over five years
- Market shares are forecasted to expand as biosimilar acceptance and regulatory approval improve
- Pricing dynamics are heavily influenced by regulatory policies, patent statuses, and payer incentives
- The market for this biosimilar is projected to generate multiple billions in global revenue by 2027
FAQs
Q1: What factors influence biosimilar pricing?
Pricing depends on regulatory approval, manufacturer competition, payer negotiations, and market acceptance.
Q2: How soon will biosimilar prices stabilize?
Prices tend to stabilize within 3-4 years after initial market entry, with gradual declines thereafter.
Q3: What is the typical market share for biosimilars in their first five years?
Usually 20-50%, depending on device convenience, physician trust, and payer policies.
Q4: Which regions lead biosimilar adoption?
Europe has higher biosimilar penetration due to earlier regulatory approval, followed by the US.
Q5: What are the main challenges for biosimilar market growth?
Patent litigation, physician acceptance, manufacturing complexities, and reimbursement policies.
References
- U.S. Food and Drug Administration. (2023). Biosimilar Product Information. Retrieved from https://www.fda.gov/drugs/biosimilars
- IQVIA. (2022). Global Biologicals Market Data.
- Deloitte. (2022). Biosimilars Market Outlook.
- Centers for Medicare & Medicaid Services (CMS). (2022). Policy updates on biosimilar reimbursement.
(Note: Data specific to NDC 60429-0934 is inferred from market patterns of biosimilars within its class; proprietary product details should be referenced from official databases.)
